Validus Patent-Cliff Exposure & CMS Drug Spending Portfolio

Validus (US): 3 reconciled FDA prescription therapies, $2.6M 2024 CMS Part D & Medicaid spend, and $486 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$1.2M
California HCAI SB 17 FilingsSpecialty launch notice ($486 intro WAC)